These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28784185)

  • 1. Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay.
    Camacho-Lovillo MS; Bulnes-Ramos A; Goycochea-Valdivia W; Fernández-Silveira L; Núñez-Cuadros E; Neth O; Pérez-Romero P
    Pediatr Rheumatol Online J; 2017 Aug; 15(1):62. PubMed ID: 28784185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis.
    Toplak N; Subelj V; Kveder T; Cucnik S; Prosenc K; Trampus-Bakija A; Todorovski L; Avcin T
    Clin Exp Rheumatol; 2012; 30(3):436-44. PubMed ID: 22513085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
    Dell'Era L; Corona F; Daleno C; Scala A; Principi N; Esposito S
    Vaccine; 2012 Jan; 30(5):936-40. PubMed ID: 22138210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis.
    Aikawa NE; Campos LM; Goldenstein-Schainberg C; Saad CG; Ribeiro AC; Bueno C; Precioso AR; Timenetsky Mdo C; Silva CA; Bonfá E
    Scand J Rheumatol; 2013; 42(1):34-40. PubMed ID: 22992045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
    Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease.
    Aikawa NE; Campos LM; Silva CA; Carvalho JF; Saad CG; Trudes G; Duarte A; Miraglia JL; Timenetsky Mdo C; Viana VS; França IL; Bonfa E; Pereira RM
    J Rheumatol; 2012 Jan; 39(1):167-73. PubMed ID: 22089462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy.
    Kanakoudi-Tsakalidou F; Trachana M; Pratsidou-Gertsi P; Tsitsami E; Kyriazopoulou-Dalaina V
    Clin Exp Rheumatol; 2001; 19(5):589-94. PubMed ID: 11579723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children.
    Esposito S; Giavoli C; Trombetta C; Bianchini S; Montinaro V; Spada A; Montomoli E; Principi N
    Vaccine; 2016 Jan; 34(1):56-60. PubMed ID: 26608327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of inactivated 2009 H1N1 influenza vaccine in pediatric liver transplant recipients.
    Torii Y; Kimura H; Ochi N; Kaneko K; Ando H; Kiuchi T; Ito Y
    Vaccine; 2011 Jun; 29(25):4187-9. PubMed ID: 21513762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab.
    Shinoki T; Hara R; Kaneko U; Miyamae T; Imagawa T; Mori M; Yokota S
    Mod Rheumatol; 2012 Nov; 22(6):871-6. PubMed ID: 22322589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.
    Launay O; Abitbol V; Krivine A; Slama LB; Bourreille A; Dupas JL; Hébuterne X; Savoye G; Deplanque D; Bouhnik Y; Pelletier AL; Galtier F; Laharie D; Nachury M; Zerbib F; Allez M; Bommelaer G; Duclos B; Lucht F; Gougeon ML; Tartour E; Rozenberg F; Hanslik T; Beaugerie L; Carrat F;
    J Crohns Colitis; 2015 Dec; 9(12):1096-107. PubMed ID: 26351392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients.
    Aikawa NE; Trudes G; Campos LM; Pereira RM; Moraes JC; Ribeiro AC; Miraglia J; Timenetsky Mdo C; Bonfa E; Silva C
    Lupus; 2013 Nov; 22(13):1394-8. PubMed ID: 24076765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus.
    Campos LM; Silva CA; Aikawa NE; Jesus AA; Moraes JC; Miraglia J; Ishida MA; Bueno C; Pereira RM; Bonfa E
    Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1121-7. PubMed ID: 23818263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.